Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
Realm Therapeutics has submitted its first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR022, as a novel treatment for atopic dermatitis (AD).
Sanofi has appointed Kathleen Tregoning, Biogen’s senior Vice President of Corporate Affairs, as a new member of the Executive Committee, effective February 27, 2017.
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
Theradiag and its South Korean partners, Professor Chang-sik Yu and his team at Asan Medical Center and CbsBioscience will receive €1.3 million financial support from Eurostars program for its Pioneer collaborative project undertaken by its Prestizia molecular biology platform.
French drugmaker focused on diabetes treatments Poxel, said it expectedly did not generate meaningful revenues in the fourth quarter of 2016, but it is on track for developing two of its programs.
The Vetoquinol Group has reported sales of €350.3 million for 2016, representing like-for-like growth of 4.3%.
Beximco Pharmaceuticals has posted earnings of $1,113,722, for the second half of 2016, compared to $944,662 to the same period last year.
Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, has reported positive topline results for a phase 3 clinical…